Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.

Abstract

Therapy with clopidogrel and aspirin, commonly known as dual antiplatelet therapy, is a widely adapted secondary prevention strategy among coronary artery disease patients treated with percutaneous coronary intervention. However, in addition to response variability and high on-treatment platelet reactivity and their relation to increased adverse events during clopidogrel therapy, candidate gene studies and genome-wide association studies have highlighted the significance of single nucleotide polymorphisms of genes associated with clopidogrel metabolism in coronary artery disease patients. Genotyping may have an emerging role in personalized antiplatelet therapy, particularly with the advent of new P2Y₁₂ receptor blockers that have more rapid and potent pharmacodynamic properties than clopidogrel. The current review discusses the role of genotyping in personalizing P2Y₁₂ receptor-blocker therapy.

• Authors: Mark J Antonino, Young-Hoon Jeong, Udaya S Tantry, Kevin P Bliden, Paul A Gurbel
• Journal: Expert review of cardiovascular therapy (Expert Rev Cardiovasc Ther) Vol. 10 Issue 8 Pg. 1011-22 (Aug 2012) ISSN: 1744-8344 [Electronic] England
• PMID: 23030291 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• P2RY12 protein, human
• Platelet Aggregation Inhibitors
• Purinergic P2Y Receptor Antagonists
• Receptors, Purinergic P2Y12

Topics

• Coronary Artery Disease (drug therapy, genetics, metabolism)
• Heterozygote
• Humans
• Pharmacogenetics (methods)
• Platelet Aggregation Inhibitors (therapeutic use)
• Precision Medicine
• Purinergic P2Y Receptor Antagonists (therapeutic use)
• Receptors, Purinergic P2Y12 (chemistry, genetics, metabolism)